TY - JOUR T1 - The Authors' reply JF - Heart JO - Heart SP - 1026 LP - 1026 DO - 10.1136/heartjnl-2011-300220 VL - 97 IS - 12 AU - Renicus S Hermanides AU - Arnoud W J van 't Hof Y1 - 2011/06/15 UR - http://heart.bmj.com/content/97/12/1026.2.abstract N2 - We thank Dr Lin and colleagues1 for their comments regarding the outcomes of 30-day major adverse cardiac events (MACE) in the pre-defined subgroup analysis of the Ongoing Tirofiban In Myocardial infarction Evaluation 2 trial (On-TIME 2).2 There are different aspects of their comments that can be addressed.First, although prehospital use of high dose tirofiban reduces the use of bail-out study medication, and this need for bail-out study medication was associated with a less … ER -